The disciplinary decisions come just days after the release of a national survey showing one high school student in five having taken a prescription drug without a doctor’s order. The findings come from a 2009 confidential survey of more than 16,000 U.S. high school students, and was the first year students were asked about prescription drug abuse.
All three students received the same suspensions which were handed down by the regional high school board and stated:
“…the student shall be removed from Ramapo High School for the remainder of the 2009-2010 school year and from September 1, 2010 through the end of the first marking period of the 2010-2011 school year, effective immediately…During the period of suspension, individual counseling services and academic support shall be made available to the student as appropriate, with the specific services offered being subject to the discretion of the Superintendent.”
The students were charged and found by the board to be guilty of the following offenses:
Student 1: “…on March 10, 2010, the student sold three (3) pills of Xanax, a controlled dangerous substance, to another high school student for thirty dollars ($30), while at Ramapo High School.”
Student 2: “The Board hereby determines, based upon a preponderance of the competent and credible evidence, that the student engaged in a scheme to distribute Xanax, as well as other controlled dangerous substances, to students of Ramapo High School, including orchestrating the purchase and distribution of such substances, to the detriment of the safety, security, and well-being of other students…”
Student 3:”The Board hereby determines, based upon a preponderance of the competent and credible evidence, that the student engaged in a scheme to distribute Xanax, a controlled dangerous substance, and did in fact distribute such substance to students of Ramapo High School away from school grounds, to the detriment of the safety, security, and well-being of other students…”
The charges and procedures followed can be read in full by clicking here.